RBC Capital analyst Shagun Singh raised the firm’s price target on Abbott to $130 from $125 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results. The firm’s industry checks suggest that Q3 underlying utilization trends were positive despite typical summer seasonality driving a sequential step-down in elective procedures, the analyst tells investors in a research note. Investor sentiment is also positive for MedTech stocks going into the earnings season, and investors are likely to continue to chase winners and catalyst-driven names into year-end, RBC added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ABT:

• Abbott initiated with an Outperform at Oppenheimer

• WHO approves Abbott Molecular mpox diagnostic test for emergency use

• Abbott price target raised to $124 from $120 at Evercore ISI

• Abbott Labs (NYSE:ABT) Goes to Trial Over Baby Formula

• Abbott pricing in higher NEC liability than expected, says Jefferies